Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04982419 · ClinicalTrials.gov registry record · Phase 2

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

A Phase 2 study of Heart Failure and Acute Kidney Injury, sponsored by VA Office of Research and Development.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
3
Study locations

NCT04982419: Recruiting Phase 2 study of Heart Failure and Acute Kidney Injury, sponsored by VA Office of Research and Development.

NCT04982419 is a Phase 2 study of Heart Failure and Acute Kidney Injury that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 240 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04982419, a Phase 2 study of Heart Failure and Acute Kidney Injury, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial is to study the effects of remote ischemic preconditioning on contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in in patients with congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary intervention.

Primary Outcome

The investigators define contrast-associated acute kidney injury as a relative increase in serum creatinine of 0.3mg/dl compared with initial creatinine at 48 hours time point after coronary angiography and/or PCI. The will obtain levels of serum creatinine at baseline, then at 24 and 48 hours time points.

Interventions

  • DEVICE Remote ischemic preconditioning
  • DEVICE Sham remote ischemic conditioning

Study Locations (3)

Pennsylvania

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA - Pittsburgh

Texas

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX - Dallas

Virginia

  • Hunter Holmes McGuire VA Medical Center, Richmond, VA - Richmond

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2021-11-01
Est. Completion 2029-03-31
Phase Phase 2
VA Office of Research and Development

1,668 total trials

What NCT04982419 shows while recruiting

NCT04982419 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (88% lower).

The record links to 5 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Remote ischemic preconditioning is the first listed.

NCT04982419 reports a single indexed study location in Pennsylvania, Texas, Virginia.

Frequently Asked Questions

What is clinical trial NCT04982419 about?

NCT04982419 is a clinical study titled "Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial". This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial is to study the effects of remote ischemic preconditioning on contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in in patients with congestive heart failure underg...

What is the current status of trial NCT04982419?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2021-11-01. Estimated completion is 2029-03-31.

What conditions does trial NCT04982419 study?

This clinical trial studies the following conditions: Heart Failure, Acute Kidney Injury, Percutaneous Coronary Intervention, Contrast Induced Nephropathy, Coronary Angiography.

What interventions are being tested in trial NCT04982419?

The interventions under investigation include: Remote ischemic preconditioning (DEVICE), Sham remote ischemic conditioning (DEVICE).

Who is sponsoring clinical trial NCT04982419?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04982419 being conducted?

This trial has 3 study locations across Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04982419's enrollment target sits among peer trials

240 151st of 397 higher than 246 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04982419, the US trial registry maintained by the National Library of Medicine. NCT04982419 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.